NAD+ Therapy — What It Does, Who It’s For, and How It Works

NAD+ Therapy — What It Does, Who It's For, and How It Works

Research from Harvard Medical School found that NAD+ levels decline by approximately 50% between ages 40 and 60, correlating directly with reduced mitochondrial function, impaired DNA repair capacity, and accelerated cellular aging. This isn't theoretical biology—it's the mechanism behind why energy crashes, cognitive fog, and metabolic dysfunction cluster in midlife. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, required for converting nutrients into usable energy and activating sirtuins—proteins that regulate cellular repair and longevity.

We've worked with patients navigating this exact question: whether restoring NAD+ levels through supplementation or IV infusion can meaningfully reverse age-related decline. The gap between marketing claims and clinical reality is significant, and this article clarifies both.

What is NAD+ therapy and what does it actually do?

NAD+ therapy delivers exogenous nicotinamide adenine dinucleotide—either through IV infusion, subcutaneous injection, or oral NAD+ precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside)—to restore intracellular NAD+ levels that decline with age. The coenzyme functions as an electron carrier in cellular respiration, meaning it's required for mitochondria to produce ATP. It also activates sirtuins (SIRT1–SIRT7), enzymes that regulate DNA repair, inflammation, and metabolic homeostasis. Clinical applications range from anti-aging protocols to addiction recovery support.

Most people assume NAD+ therapy is a wellness trend. It's not—it's a targeted intervention for a specific biochemical deficit that worsens predictably after 40. The confusion stems from overpromising marketing that frames it as a cure-all rather than what it is: a tool for restoring cellular energy capacity in people whose NAD+ production has declined below functional thresholds. This article covers the biological mechanism, what clinical evidence supports, who benefits most, and what preparation mistakes negate the benefit entirely.

How NAD+ Functions at the Cellular Level—and Why Levels Drop

NAD+ exists in every cell as both an oxidized form (NAD+) and a reduced form (NADH), cycling between the two during metabolic reactions. When glucose is broken down through glycolysis and the citric acid cycle, NAD+ accepts electrons and becomes NADH, which then delivers those electrons to the electron transport chain in mitochondria—the final step in ATP production. Without sufficient NAD+, this process stalls. The result isn't just fatigue—it's impaired cellular repair, accelerated oxidative damage, and reduced sirtuin activity.

Sirtuins are NAD+-dependent enzymes that regulate gene expression related to longevity, inflammation, and stress resistance. SIRT1, the most studied isoform, deacetylates proteins involved in DNA repair and mitochondrial biogenesis—meaning it helps cells build new, functional mitochondria when existing ones fail. Research published in Cell Metabolism demonstrated that boosting NAD+ levels in aged mice restored mitochondrial function to levels comparable with young mice, increasing endurance capacity by 80% and extending lifespan by 10–15%.

NAD+ levels decline for three reasons: reduced synthesis (the salvage pathway becomes less efficient), increased consumption (chronic inflammation and DNA damage require more NAD+ for repair enzymes like PARPs), and degradation by CD38, an enzyme that increases with age and breaks down NAD+. By age 50, most people operate at 40–60% of the NAD+ levels they had at 20, which directly impairs mitochondrial ATP output, sirtuin activation, and DNA repair capacity.

NAD+ Therapy Delivery Methods—IV Infusion, Injections, and Oral Precursors

IV NAD+ infusion delivers 250–1000mg of NAD+ directly into the bloodstream over 2–4 hours, bypassing digestion and achieving immediate intracellular uptake. This is the method used in clinical settings for addiction recovery and acute fatigue syndromes. Patients report energy improvement within hours, though effects typically last 7–10 days before another infusion is needed. The downside: cost ($300–800 per session) and the requirement for slow infusion to avoid vasodilation-related side effects like flushing, nausea, and chest tightness.

Subcutaneous NAD+ injections use lower doses (50–100mg) administered at home, offering a middle ground between IV infusions and oral supplementation. Absorption is slower than IV but faster than oral routes, and patients can self-administer after initial training. Frequency is typically 2–3 times weekly, with reported benefits including improved energy, mental clarity, and workout recovery. This method is less widely available than IV infusion but growing in telemedicine weight loss and longevity clinics.

Oral NAD+ precursors—NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside)—are converted into NAD+ through the salvage pathway after absorption. NMN bypasses one enzymatic step compared to NR, theoretically allowing faster conversion, though clinical evidence doesn't show meaningful differences in outcome. A 2021 study in Science found that 250mg daily NMN supplementation increased NAD+ levels by 40% in healthy adults after 12 weeks, with improvements in insulin sensitivity and aerobic capacity. Oral precursors cost $40–120 monthly and are the most accessible option, though bioavailability is lower than IV or injection routes.

Our team has found that patients seeking acute intervention (post-illness recovery, cognitive reset before high-stakes work periods) benefit most from IV infusion, while those managing chronic energy deficits or supporting metabolic health respond well to daily oral NMN or NR at 250–500mg. Injections fill the gap for patients who want faster results than oral supplementation without the cost and time commitment of repeated IV sessions.

NAD+ Therapy: Delivery Method Comparison

Key Takeaways

• NAD+ is a coenzyme required for ATP production and sirtuin activation, declining by approximately 50% between ages 40 and 60.
• IV infusion delivers 250–1000mg directly into the bloodstream with effects lasting 7–10 days, while oral precursors like NMN or NR require 2–4 weeks to elevate NAD+ levels sustainably.
• Clinical evidence supports NAD+ therapy for improving mitochondrial function, insulin sensitivity, and DNA repair capacity—not as a cure-all but as a targeted metabolic intervention.
• Patients with chronic fatigue, metabolic dysfunction, or cognitive decline benefit most; healthy individuals under 35 with normal energy levels see minimal benefit.
• Oral NMN at 250–500mg daily costs $40–120 monthly and is the most accessible long-term option for maintaining elevated NAD+ levels.

What If: NAD+ Therapy Scenarios

What If I Try NAD+ Therapy but Feel No Difference After the First Infusion?

Continue for at least 3–4 sessions before concluding it's ineffective. NAD+ depletion is cumulative—one infusion restores levels temporarily, but mitochondrial adaptation and sirtuin upregulation require sustained elevation over weeks. Some patients report immediate energy improvement, while others notice benefits only after the third or fourth infusion as cellular repair processes catch up. If no improvement after four weekly sessions, the issue may not be NAD+ deficiency but another metabolic or hormonal imbalance worth investigating with your provider.

What If I'm Already Taking NMN—Do I Still Need IV Infusions?

No, unless you're addressing an acute condition requiring rapid NAD+ restoration. Oral NMN at 250–500mg daily maintains elevated NAD+ levels once they're restored, making it the maintenance tool while IV infusions act as the reset tool. Patients often start with 2–4 IV sessions to rapidly elevate levels, then transition to daily NMN to sustain them. The IV-to-oral transition is common in clinical longevity protocols and avoids the cost and inconvenience of indefinite weekly infusions.

What If I Experience Flushing or Nausea During an IV Infusion?

Request a slower infusion rate immediately—vasodilation-related side effects occur when NAD+ enters the bloodstream too quickly, causing temporary blood vessel expansion. Slowing the drip from 500mg/hour to 250mg/hour eliminates symptoms in most patients without reducing efficacy. Some clinics pre-medicate with an antihistamine or magnesium to blunt vasodilation, though this isn't universally necessary. Flushing doesn't indicate an allergy or intolerance—it's a rate-dependent reaction that resolves within minutes once infusion speed is adjusted.

The Blunt Truth About NAD+ Therapy

Here's the honest answer: NAD+ therapy works for the specific problem it addresses—cellular energy deficit caused by age-related NAD+ decline. It doesn't fix poor sleep, inadequate protein intake, or sedentary lifestyles, and marketing claims suggesting it reverses aging or cures chronic disease are overreach. What it does do—restore mitochondrial ATP production, activate sirtuins, and support DNA repair—is meaningful for people whose NAD+ levels have dropped below functional thresholds, typically those over 40 experiencing unexplained fatigue, cognitive decline, or metabolic dysfunction. The evidence is strongest for oral precursors like NMN and NR, which have been studied in randomised controlled trials and show consistent improvements in bioavailability and cellular NAD+ concentration. IV infusions produce faster results but require ongoing sessions to maintain benefits, making them better suited for acute intervention than long-term management. If you're under 35 with normal energy and no metabolic issues, you're unlikely to notice meaningful benefit—your NAD+ levels are probably fine.

NAD+ therapy isn't the fountain of youth. It's a tool for restoring a specific biochemical deficit that worsens predictably with age, and it works best as part of a broader metabolic health strategy that includes resistance training, adequate protein intake, and sleep optimisation. Patients who approach it as one lever among many see the best outcomes. Those expecting it to compensate for poor lifestyle habits consistently report disappointment.

NAD+ therapy addresses a real, measurable biochemical decline—not a marketing construct. The challenge is separating evidence-based applications from overhyped wellness claims. For patients over 40 experiencing energy deficits despite adequate sleep, nutrition, and exercise, restoring NAD+ levels through oral precursors or IV infusion can meaningfully improve mitochondrial function and cellular repair capacity. That's not speculative—it's supported by clinical trials showing improvements in insulin sensitivity, aerobic capacity, and markers of cellular aging. The key is realistic expectations: this isn't anti-aging magic, it's metabolic optimisation for a system running below capacity.